Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies
Ranjeet Prasad Dash, Ramapuram Jayachandra Babu, Nuggehally R. Srinivas · European Journal of Drug Metabolism and Pharmacokinetics · 2017
Cited by 85 works. doi:10.1007/s13318-017-0411-4
Authors
References
- Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
- Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
- EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
- Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein
- P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
- Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
- Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
- The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
- P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
- Effect of quercetin on hoechst 33342 transport by purified and reconstituted p-glycoprotein